Houston Methodist met the challenge of translation early in the design of the research institute building. It houses the essential services and technology that support the full cycle of development to efficiently and effectively deliver innovations to the clinic.

Translating laboratory innovations into treatments for patients is fraught with challenges. The lack of specialized translational research resources makes it extremely difficult and expensive for most institutions to turn fundamental discoveries into tangible solutions that benefit the public. Their most promising innovations perish in the 'Valley of Death" before they reach the clinic. We provide support at every step of the cycle of a cure from bridge funding to technical expertise with U.S. Food and Drug Administration (FDA)-approved current good manufacturing practice (cGMP) facilities, good laboratory practice (GLP) facilities and clinical trial operations. T2 translation allows for the testing of new interventions in a controlled environment and allots time to gain knowledge about the ability of an intervention in an optimal setting. The most promising innovations have a lifeline at Houston Methodist.